Beijing SL Pharmaceutical Co Ltd (002038) — Financial Flexibility Index
Beijing SL Pharmaceutical Co Ltd (002038) has a Financial Flexibility Index of 0.24x as of September 2025. Free cash flow of CN¥77.90 Million (operating CF CN¥66.55 Million minus capex CN¥11.35 Million) represents 0% of total liabilities (CN¥327.96 Million). Check asset allocation strategy of Beijing SL Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Beijing SL Pharmaceutical Co Ltd Financial Flexibility Index (2003–2025)
Historical Financial Flexibility Index trend for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. See working capital to net assets of Beijing SL Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year free cash flow to debt coverage for Beijing SL Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see 002038 market cap overview.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.51x | CN¥450.63 Million | CN¥257.66 Million | CN¥883.49 Million | ▼ -64.5% |
| 2024 | 1.44x | CN¥572.87 Million | CN¥225.49 Million | CN¥398.37 Million | ▼ -0.9% |
| 2023 | 1.45x | CN¥678.56 Million | CN¥460.20 Million | CN¥467.72 Million | ▲ +4.0% |
| 2022 | 1.40x | CN¥553.31 Million | CN¥389.82 Million | CN¥396.60 Million | ▼ -13.6% |
| 2021 | 1.62x | CN¥701.54 Million | CN¥464.63 Million | CN¥434.23 Million | ▼ -1.4% |
| 2020 | 1.64x | CN¥671.79 Million | CN¥415.84 Million | CN¥410.09 Million | ▼ -29.5% |
| 2019 | 2.32x | CN¥938.61 Million | CN¥665.83 Million | CN¥403.76 Million | ▲ +53.3% |
| 2018 | 1.52x | CN¥712.55 Million | CN¥485.17 Million | CN¥469.73 Million | ▼ -29.0% |
| 2017 | 2.14x | CN¥610.37 Million | CN¥380.72 Million | CN¥285.67 Million | ▼ -42.4% |
| 2016 | 3.71x | CN¥561.07 Million | CN¥396.86 Million | CN¥151.19 Million | ▼ -13.2% |
| 2015 | 4.28x | CN¥634.55 Million | CN¥504.87 Million | CN¥148.40 Million | ▼ -4.3% |
| 2014 | 4.47x | CN¥616.02 Million | CN¥465.00 Million | CN¥137.92 Million | ▲ +20.3% |
| 2013 | 3.71x | CN¥456.89 Million | CN¥347.41 Million | CN¥123.09 Million | ▼ -39.6% |
| 2012 | 6.15x | CN¥646.49 Million | CN¥398.60 Million | CN¥105.17 Million | ▲ +2.9% |
| 2011 | 5.97x | CN¥301.64 Million | CN¥228.59 Million | CN¥50.52 Million | ▼ -21.0% |
| 2010 | 7.55x | CN¥281.18 Million | CN¥238.13 Million | CN¥37.22 Million | ▲ +35.5% |
| 2009 | 5.57x | CN¥204.86 Million | CN¥174.41 Million | CN¥36.75 Million | ▼ -33.7% |
| 2008 | 8.41x | CN¥217.93 Million | CN¥194.32 Million | CN¥25.91 Million | ▲ +154.0% |
| 2007 | 3.31x | CN¥114.98 Million | CN¥88.36 Million | CN¥34.71 Million | ▼ -4.2% |
| 2006 | 3.46x | CN¥122.50 Million | CN¥57.55 Million | CN¥35.41 Million | ▼ -37.1% |
| 2005 | 5.50x | CN¥128.72 Million | CN¥47.48 Million | CN¥23.42 Million | ▲ +218.3% |
| 2004 | 1.73x | CN¥49.00 Million | CN¥31.26 Million | CN¥28.38 Million | ▲ +35.1% |
| 2003 | 1.28x | CN¥46.99 Million | CN¥30.55 Million | CN¥36.78 Million | — |